Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Apollomics Inc Receives China Investigational New Drug Approval For Apl 106 To Initiate A Phase 3 Bridging Study In Acute Myeloid Leukemia is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
China’s NMPA grants conditional approval for Apollomics’ NSCLC drug
Velbretinib (APL ... Phase I/II study. In an October 31 press release, Apollomics’s CEO Dr Guo-Liang Yu said: “The NMPA approval of velbretinib is an important milestone toward providing a new ... Read More
Apollomics, Inc. (APLM)
April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics ... of enrollment in its Phase 3 bridging study evaluating uproleselan (APL-106), an investigational, first-in-class E-selectin ... Read More
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical ... Read More
Dimerix gains on China drug application approval
Dimerix receives approval of investigational new drug application for ACTION3 trial in China No bridging studies required ... recruitment for its ACTION3 Phase 3 study of DMX-200, for focal ... Read More
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics ... and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard ... Read More
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics is conducting a multi-cohort Phase 2 study of ... to treat acute myeloid leukemia. Cautionary Statement Regarding Forward-Looking StatementsThis press release includes statements ... Read More
SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis
JERUSALEM, April 3, 2024 /PRNewswire ... U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 study for SPL84 in ... Read More
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Apollomics Inc ... uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Read More
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
In addition, we finished patient enrollment for our Phase 3 bridging study in China ... acute myeloid leukemia. For more information, please visit https://www.apollomics.com. This press release ... Read More
Apollomics Inc.: Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program Completed patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus